H.C. Wainwright Reiterates a Hold Rating on Ortho Clinical Diagnostics Holdings (OCDX)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on Ortho Clinical Diagnostics Holdings (OCDXResearch Report), with a price target of $24.68. The company’s shares closed last Wednesday at $16.32, close to its 52-week low of $15.53.

According to, Chen is a 4-star analyst with an average return of 14.7% and a 37.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Stealth Biotherapeutics.

Currently, the analyst consensus on Ortho Clinical Diagnostics Holdings is a Moderate Buy with an average price target of $23.56.

See today’s best-performing stocks on TipRanks >>

Ortho Clinical Diagnostics Holdings’ market cap is currently $3.94B and has a P/E ratio of -42.17.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ortho Clinical Diagnostics Holdings PLC offers in vitro diagnostics solutions and services. It provides diagnostic testing solutions to the clinical laboratory and transfusion medicine communities. The company operates through three geographic segments such as North America, EMEA, and Greater China. North America segment generates most of the revenue for firm.

Read More on OCDX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More